Methotrexate in the Treatment of Chronic Idiopathic Urticaria

PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2016

Conditions
Chronic Urticaria
Interventions
DRUG

Methotrexate (Novatrex ®) + anti-H1

"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."

DRUG

Placebo + anti-H1

"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."

Trial Locations (11)

29000

CHRU BREST Morvan, Brest

35000

CHRU RENNES Pontchaillou, Rennes

37044

Chru Tours, Tours

44000

Chru Nantes, Nantes

51000

Chru Reims, Reims

54000

CHRU NANCY Brabois, Nancy

59000

CHRU LILLE Huriez, Lille

72000

Ch Le Mans, Le Mans

75020

Hopital TENON, Paris

86000

CHRU POITIERS La Miléterie, Poitiers

94000

Chu Mondor, Créteil

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT01960283 - Methotrexate in the Treatment of Chronic Idiopathic Urticaria | Biotech Hunter | Biotech Hunter